0.00
—
Close of 30 Oct 2026, in USD
About Proto Script Pharmaceutical
Its shares trade under the ticker PSCR. It has been listed since 25 November 2011. In the fiscal year to 31 December 2015, it reported revenue of $881,442 and a net loss of $145,249. At that date it held total assets of $198,941 and shareholders' equity of $62,242.
Proto Script Pharmaceutical Corp. engages in the provision of mobility solutions. The company is headquartered in Rancho Cucamonga, California. The company went IPO on 2011-11-25. The firm is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. The firm has various contracts with state and governmental insurance providers, among others. These contracts provide the Company the right to sell and repair DME. The firm's health care insurance contracts allow it the ability to service patients nationally. The firm intends to expand its market through additional contracts and open several repair facilities throughout the continental United States. The firm currently has repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California. As of June 30, 2016, the Company had not generated any revenues.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 25 Nov 2011
Leadership
Pay as last reported
- Ms. Michelle RicoPresident, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director, since 2016
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Proto Script Pharmaceutical Corp has a strong and experienced management team, who possess extensive knowledge and expertise in the pharmaceutical industry. This enables the company to make informed decisions and effectively navigate the complex landscape.
- The company has a robust research and development (R&D) department, which continually explores new drug formulations and technologies. This allows Proto Script Pharmaceutical Corp to stay innovative and maintain a competitive edge in the market.
- Proto Script Pharmaceutical Corp has established a strong brand reputation for delivering high-quality pharmaceutical products. The company's commitment to maintaining rigorous quality control standards has gained the trust and loyalty of healthcare professionals and patients alike.
Weaknesses
- One weakness of Proto Script Pharmaceutical Corp is its heavy reliance on a limited number of key products. This concentration of revenue poses a risk, as any adverse events or market changes affecting those products could have a significant negative impact on the company's financial performance.
- The company may face challenges in securing regulatory approvals for new drug candidates, leading to potential delays in product launches and revenue generation. This could hinder Proto Script Pharmaceutical Corp's ability to expand its product portfolio and compete effectively.
- Proto Script Pharmaceutical Corp might also lack a diversified customer base in certain geographical regions. This dependency on a few markets increases vulnerability to changes in local regulations, economic conditions, and geopolitical factors.
Opportunities
- The increasing global demand for pharmaceutical products presents a significant growth opportunity for Proto Script Pharmaceutical Corp. The company can leverage its R&D capabilities to develop new drugs and expand its market reach, especially in emerging markets.
- Proto Script Pharmaceutical Corp can explore strategic partnerships or acquisitions to broaden its product portfolio and gain access to new technologies. Such collaborations can enhance the company's competitiveness and drive revenue growth.
- The growing importance of personalized medicine and advancements in genetic research provide an opportunity for Proto Script Pharmaceutical Corp to develop targeted therapies that cater to specific patient populations. This could result in improved treatment outcomes and considerable market differentiation.
Threats
- Proto Script Pharmaceutical Corp faces intense competition from both established pharmaceutical companies and emerging biotech startups. This competitive landscape poses a threat to the company's market share and profitability.
- Changes in healthcare policies, regulations, or pricing structures could impact the pricing and reimbursement of pharmaceutical products. This can lead to pricing pressures and reduced profitability for Proto Script Pharmaceutical Corp.
- The emergence of counterfeit drugs and intellectual property infringements poses a threat to Proto Script Pharmaceutical Corp's brand reputation and revenue. The company needs to invest in robust anti-counterfeit measures and proactive intellectual property protection strategies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.